Stay updated on Durvalumab in Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Cervical Cancer Clinical Trial page.

Latest updates to the Durvalumab in Cervical Cancer Clinical Trial page
- Check4 days agoChange DetectedA sitewide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page. The ClinicalTrials.gov revision number changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1 while the study record page continued to display a 403 error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe CALLA study record page now displays a 403 Forbidden error, indicating that access to the study content is blocked.SummaryDifference17%

- Check39 days agoChange DetectedThe page shows a new Revision: v3.7.0 replacing the previous v3.6.6, indicating a new deployment/build of the site. This appears to be a maintenance/versioning change rather than an update to study details or user-facing actions.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6 in the page footer, signaling a new page version. This update does not alter the study content or how the page functions.SummaryDifference0.0%

- Check60 days agoChange DetectedAn NIH funding note was added under the study IDs, detailing the 2018 U.S. NIH Grant/Contract support for the trial.SummaryDifference0.0%

Stay in the know with updates to Durvalumab in Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Cervical Cancer Clinical Trial page.